A Study to Evaluate the Efficacy and Safety of CnU Cap. 500 mg in Patients With Biliary Dyspepsia

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: Biliary Dyspepsia

In brief

The objective of this clinical trial is to evaluate the efficacy and safety of CnU capsule 500 mg administration in patients with biliary dyspepsia

Key facts

Study ID

NCT07016269

Run by

Myungmoon Pharma. Co. Ltd.

People needed

358

Starts

2025-08-29

Expected to finish

2028-06-13

Last updated by the study team

2026-07-29

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Korea University Ansan Hospital — Ansan, Gyeonggi-do, South Korea (enrolling)
• Ajou University Hospital — Suwon, Gyeonggi-do, South Korea (enrolling)
• Pusan National University Hospital — Busan, South Korea (enrolling)
• CHA Bundang Medical Center — Gyeonggi-do, South Korea (enrolling)
• Hallym University Dongtan Sacred Heart Hospital — Gyeonggi-do, South Korea (enrolling)
• Soonchunhyang University Cheonan Hospital — Gyeonggi-do, South Korea (enrolling)
• Inha University Hospital — Incheon, South Korea (enrolling)
• Gangnam Severance Hospital — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.